Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Summary
In 12,257 patients with atherosclerosis or diabetes and no prior MI or stroke, evolocumab reduced first cardiovascular events over 4.6 years (HR 0.75 for 3-point MACE; HR 0.81 for 4-point MACE) with no safety signal. These data extend event reduction with PCSK9 inhibition into a broader primary prevention population meeting LDL-C ≥90 mg/dL.
Key Findings
- Evolocumab reduced 3-point MACE (HR 0.75; 95% CI 0.65–0.86; P<0.001).
- Evolocumab reduced 4-point MACE including ischemia-driven revascularization (HR 0.81; 95% CI 0.73–0.89; P<0.001).
- Safety profiles were similar to placebo over a median of 4.6 years.
Clinical Implications
Consider evolocumab for high-risk patients (atherosclerosis or diabetes) with LDL-C ≥90 mg/dL who remain above targets despite guideline-directed therapy; shared decision-making should weigh absolute risk, cost, and access.
Why It Matters
A large, rigorous outcome trial showing PCSK9 inhibitors reduce first events in patients without prior MI/stroke may shift primary prevention strategies in high-risk populations inadequately controlled on standard therapy.
Limitations
- Absolute risk reduction may be modest in some subgroups; cost-effectiveness varies by healthcare system
- Generalizability limited to patients meeting LDL-C ≥90 mg/dL and enrolled risk profiles
Future Directions
Evaluate cost-effectiveness and implementation strategies in primary prevention, define optimal patient selection and combination with ezetimibe/high-intensity statins, and assess longer-term safety.
Study Information
- Study Type
- RCT
- Research Domain
- Prevention/Treatment
- Evidence Level
- I - Large double-blind randomized placebo-controlled cardiovascular outcomes trial
- Study Design
- OTHER